Solutia Europe Agrees to Sell Pharmaceutical Services Business
Solutia Inc. (St. Louis, MO) announced that its subsidiary, Solutia Europe SA/NV (SESA), had reached a definitive agreement to sell its pharmaceutical services business, which comprises CarboGen AG and AMCIS AG. Under the terms of the agreement, Dishman Pharmaceuticals and Chemicals Ltd. (Ahmedabad, India) will purchase 100 percent of CarboGen and AMCIS stock and related assets for $74.5 million, subject to a working capital adjustment.
On May 24, Solutia Inc. (St. Louis, MO, www.solutia.com)announced that its subsidiary, Solutia Europe SA/NV (SESA), reached a definitive agreement to sell its pharmaceutical servicesbusiness, which comprises CarboGen AG and AMCIS AG. Under the terms ofthe agreement, Dishman Pharmaceuticals and Chemicals Ltd. (Ahmedabad,India, www.dishmangroup.com)will purchase 100% of CarboGen and AMCIS stock and related assets for$74.5 million, subject to a working capital adjustment. Completion ofthe transaction is subject to the removal of the restrictions relatedto the sale under SESA's Euronotes, authorization by the bankruptcycourt overseeing Solutia's reorganization, and government andregulatory approvals, which are expected by Aug. 31. The transactionincludes the pharmaceutical services business's intellectual property,patents, trademarks, customer contracts, and employees.
CarboGen and AMCIS provide drug development and commercializationservices to pharmaceutical and biotechnology companies. The companies'2005 sales totaled approximately CHF 80 million ($65.4 million). Thepharmaceutical services business has research and developmentfacilities at three sites in Switzerland: Aarau, Bubendorf, andNeuland.
Dishman Pharmaceuticals and Chemicals manufactures activepharmaceutical ingredients and intermediates, quaternary compounds, andfine chemicals.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
